{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:06:58Z","timestamp":1789538818246,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05836-2","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:00:16Z","timestamp":1789538416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From virtual screening to cell-based assays: structure-guided identification of EGFR-targeting perimidine derivatives with anticancer activity"],"prefix":"10.1007","author":[{"given":"Meera","family":"Gopinadh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreehari A.","family":"P","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunish K.","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Ashif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unnikrishnan","family":"Sivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobhi","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"5836_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2174\/157017807781212175","volume":"4","author":"K Arya","year":"2007","unstructured":"Arya K, Dandia A (2007) Regioselective synthesis of biologically important scaffold spiro[indole-perimidines]: an antitumor agents. Lett Org Chem 4:378\u2013383. https:\/\/doi.org\/10.2174\/157017807781212175","journal-title":"Lett Org Chem"},{"key":"5836_CR2","doi-asserted-by":"publisher","unstructured":"Asveda T, Talwar P, Ravanan P (2026) Evaluating the reliability of virtual screening: experimental insights from flavonoid library screen targeting caspase-3. FASEB Journal 40. https:\/\/doi.org\/10.1096\/fj.202504176R","DOI":"10.1096\/fj.202504176R"},{"key":"5836_CR3","doi-asserted-by":"publisher","unstructured":"Bao B, Mitrea C, Wijesinghe P, et al (2017) Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity. Sci Rep 7. https:\/\/doi.org\/10.1038\/srep44125","DOI":"10.1038\/srep44125"},{"key":"5836_CR4","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1200\/JCO.2005.08.326","volume":"23","author":"J Baselga","year":"2005","unstructured":"Baselga J, Albanell J, Ruiz A et al (2005) Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23:5323\u20135333. https:\/\/doi.org\/10.1200\/JCO.2005.08.326","journal-title":"J Clin Oncol"},{"key":"5836_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113854","volume":"176","author":"N Batis","year":"2021","unstructured":"Batis N, Brooks JM, Payne K et al (2021) Lack of predictive tools for conventional and targeted cancer therapy: barriers to biomarker development and clinical translation. Adv Drug Deliv Rev 176:113854. https:\/\/doi.org\/10.1016\/j.addr.2021.113854","journal-title":"Adv Drug Deliv Rev"},{"key":"5836_CR6","doi-asserted-by":"publisher","unstructured":"Emran T Bin, Shahriar A, Mahmud AR, et al (2022) Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol 12. https:\/\/doi.org\/10.3389\/fonc.2022.891652","DOI":"10.3389\/fonc.2022.891652"},{"key":"5836_CR7","doi-asserted-by":"publisher","unstructured":"Dong C, Wu J, Chen Y, et al (2021) Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol 12. https:\/\/doi.org\/10.3389\/fphar.2021.628690","DOI":"10.3389\/fphar.2021.628690"},{"key":"5836_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2021.100103","volume":"2","author":"X Du","year":"2021","unstructured":"Du X, Yang B, An Q et al (2021) Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. Innovation 2:100103. https:\/\/doi.org\/10.1016\/j.xinn.2021.100103","journal-title":"Innovation"},{"key":"5836_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10549-024-07374-y","volume":"207","author":"T Fang","year":"2024","unstructured":"Fang T, Hu S, Song X et al (2024) Combination of monensin and erlotinib synergistically inhibited the growth and cancer stem cell properties of triple-negative breast cancer by simultaneously inhibiting EGFR and PI3K signaling pathways. Breast Cancer Res Treat 207:435\u2013451. https:\/\/doi.org\/10.1007\/s10549-024-07374-y","journal-title":"Breast Cancer Res Treat"},{"key":"5836_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/ardp.201200486","volume":"346","author":"TA Farghaly","year":"2013","unstructured":"Farghaly TA, Mahmoud HK (2013) Synthesis, tautomeric structures, and antitumor activity of new perimidines. Arch Pharm (Weinheim) 346:392\u2013402. https:\/\/doi.org\/10.1002\/ardp.201200486","journal-title":"Arch Pharm (Weinheim)"},{"key":"5836_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2174\/1385272824999201124141506","volume":"25","author":"NA Harry","year":"2020","unstructured":"Harry NA, Ujwaldev SM, Aneeja T, Anilkumar G (2020) A comprehensive overview of perimidines: synthesis, chemical transformations, and applications. Curr Org Chem 25:248\u2013271. https:\/\/doi.org\/10.2174\/1385272824999201124141506","journal-title":"Curr Org Chem"},{"key":"5836_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2174\/1385272824999201124141506","volume":"25","author":"NA Harry","year":"2021","unstructured":"Harry NA, Ujwaldev SM, Aneeja T, Anilkumar G (2021) A comprehensive overview of perimidines: synthesis, chemical transformations, and applications. Curr Org Chem 25:248\u2013271. https:\/\/doi.org\/10.2174\/1385272824999201124141506","journal-title":"Curr Org Chem"},{"key":"5836_CR13","doi-asserted-by":"publisher","first-page":"44247","DOI":"10.1039\/D0RA09198G","volume":"10","author":"MM Heravi","year":"2020","unstructured":"Heravi MM, Zadsirjan V (2020) Prescribed drugs containing nitrogen heterocycles: an overview. RSC Adv 10:44247\u201344311","journal-title":"RSC Adv"},{"key":"5836_CR14","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.15001617.v1","author":"H Ibrahim","year":"2026","unstructured":"Ibrahim H, Ibrahim Y, Backenk\u00f6hler M et al (2026) MolDockLab: a data-driven workflow for balanced consensus docking in hit identification. ChemRxiv. https:\/\/doi.org\/10.26434\/chemrxiv.15001617.v1","journal-title":"ChemRxiv"},{"key":"5836_CR15","doi-asserted-by":"publisher","first-page":"29286","DOI":"10.18632\/oncotarget.25389","volume":"9","author":"RMC Ignacio","year":"2018","unstructured":"Ignacio RMC, Gibbs CR, Lee E-S, Son D-S (2018) The TGF\u03b1-EGFR-Akt signaling axis plays a role in enhancing proinflammatory chemokines in triple-negative breast cancer cells. Oncotarget 9:29286\u201329303. https:\/\/doi.org\/10.18632\/oncotarget.25389","journal-title":"Oncotarget"},{"key":"5836_CR16","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11274","author":"W Jiang","year":"2020","unstructured":"Jiang W, Wang X, Zhang C et al (2020) Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer. Oncol Lett. https:\/\/doi.org\/10.3892\/ol.2020.11274","journal-title":"Oncol Lett"},{"key":"5836_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11030-017-9790-3","volume":"22","author":"A Kumar","year":"2018","unstructured":"Kumar A, Banerjee S, Roy P et al (2018) Solvent-free synthesis and anticancer activity evaluation of benzimidazole and perimidine derivatives. Mol Divers 22:113\u2013127. https:\/\/doi.org\/10.1007\/s11030-017-9790-3","journal-title":"Mol Divers"},{"key":"5836_CR18","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.2174\/1871520620666200705214917","volume":"20","author":"DK Lang","year":"2020","unstructured":"Lang DK, Kaur R, Arora R et al (2020) Nitrogen-containing heterocycles as anticancer agents: an overview. Anticancer Agents Med Chem 20:2150\u20132168. https:\/\/doi.org\/10.2174\/1871520620666200705214917","journal-title":"Anticancer Agents Med Chem"},{"key":"5836_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1107\/S0021889892009944","volume":"26","author":"RA Laskowski","year":"1993","unstructured":"Laskowski RA, MacArthur MW, Moss DS, Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26:283\u2013291. https:\/\/doi.org\/10.1107\/S0021889892009944","journal-title":"J Appl Crystallogr"},{"key":"5836_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2174\/1385272827666221227120648","volume":"27","author":"PV Ledade","year":"2022","unstructured":"Ledade PV, Lambat TL, Gunjate JK et al (2022) Nitrogen-containing fused heterocycles: organic synthesis and applications as potential anticancer agents. Curr Org Chem 27:206\u2013222. https:\/\/doi.org\/10.2174\/1385272827666221227120648","journal-title":"Curr Org Chem"},{"key":"5836_CR21","doi-asserted-by":"publisher","first-page":"48404","DOI":"10.1039\/c7ra09825a","volume":"7","author":"HY Lin","year":"2017","unstructured":"Lin HY, Sun WX, Zheng CS et al (2017) Synthesis, characterization and biological evaluation of formononetin derivatives as novel EGFR inhibitors: via inhibiting growth, migration and inducing apoptosis in breast cancer cell line. RSC Adv 7:48404\u201348419. https:\/\/doi.org\/10.1039\/c7ra09825a","journal-title":"RSC Adv"},{"key":"5836_CR22","doi-asserted-by":"publisher","unstructured":"Liu Y, Ma X, Zhu Y, et al (2022) pH-responsive nanomedicine co-encapsulated with Erlotinib and chlorin e6 can enable effective treatment of triple negative breast cancer via reprogramming tumor vasculature. Chemical Engineering Journal 437. https:\/\/doi.org\/10.1016\/j.cej.2022.135305","DOI":"10.1016\/j.cej.2022.135305"},{"key":"5836_CR23","doi-asserted-by":"publisher","unstructured":"Ma Y, Fang Z, Zhang H, et al (2024) PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway. Cell Death Dis 15. https:\/\/doi.org\/10.1038\/s41419-024-06502-2","DOI":"10.1038\/s41419-024-06502-2"},{"key":"5836_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-012-2289-9","volume":"136","author":"H Masuda","year":"2012","unstructured":"Masuda H, Zhang D, Bartholomeusz C et al (2012) Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 136:331\u2013345. https:\/\/doi.org\/10.1007\/s10549-012-2289-9","journal-title":"Breast Cancer Res Treat"},{"key":"5836_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/cells7110212","volume":"7","author":"T Nagano","year":"2018","unstructured":"Nagano T, Tachihara M, Nishimura Y (2018) Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Cells 7:212. https:\/\/doi.org\/10.3390\/cells7110212","journal-title":"Cells"},{"key":"5836_CR26","doi-asserted-by":"publisher","unstructured":"Ortega E, Zamora A, Basu U, et al (2020) An erlotinib gold(I) conjugate for combating triple-negative breast cancer. J Inorg Biochem 203. https:\/\/doi.org\/10.1016\/j.jinorgbio.2019.110910","DOI":"10.1016\/j.jinorgbio.2019.110910"},{"issue":"26","key":"5836_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202301200","volume":"8","author":"R Pal","year":"2023","unstructured":"Pal R, Teli G, Swamy Purawarga Matada G, Dhiwar PS (2023) Nitrogen-containing heterocyclic scaff olds as EGFR inhibitors: design approaches, molecular docking, and structure-activity relationships. ChemistrySelect 8(26):e202301200. https:\/\/doi.org\/10.1002\/slct.202301200","journal-title":"ChemistrySelect"},{"key":"5836_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1042\/BJ20121513","volume":"448","author":"JH Park","year":"2012","unstructured":"Park JH, Liu Y, Lemmon MA, Radhakrishnan R (2012) Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem J 448:417\u2013423. https:\/\/doi.org\/10.1042\/BJ20121513","journal-title":"Biochem J"},{"key":"5836_CR29","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","volume":"187","author":"A Passaro","year":"2024","unstructured":"Passaro A, Al Bakir M, Hamilton EG et al (2024) Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell 187:1617\u20131635. https:\/\/doi.org\/10.1016\/j.cell.2024.02.041","journal-title":"Cell"},{"key":"5836_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejmech.2017.05.027","volume":"142","author":"H Patel","year":"2017","unstructured":"Patel H, Pawara R, Ansari A, Surana S (2017) Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance. Eur J Med Chem 142:32\u201347. https:\/\/doi.org\/10.1016\/j.ejmech.2017.05.027","journal-title":"Eur J Med Chem"},{"key":"5836_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19930-w","volume":"8","author":"Y Rai","year":"2018","unstructured":"Rai Y, Pathak R, Kumari N et al (2018) Mitochondrial biogenesis and metabolic hyperactivation limits the application of MTT assay in the estimation of radiation induced growth inhibition. Sci Rep 8:1531. https:\/\/doi.org\/10.1038\/s41598-018-19930-w","journal-title":"Sci Rep"},{"key":"5836_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2024.101490","volume":"7","author":"R Raju","year":"2024","unstructured":"Raju R, Joy AJ, Nulgumnalli Manjunathaiah R et al (2024) EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: a critical review. Results Chem 7:101490. https:\/\/doi.org\/10.1016\/j.rechem.2024.101490","journal-title":"Results Chem"},{"key":"5836_CR33","doi-asserted-by":"publisher","unstructured":"Ranjitha KVB, Loke SK, Tanneeru K, et al (2026) Design, synthesis and cytotoxic assessment of new imidazo[1,2-a]pyridine containing isoxazole derivatives as potent anticancer agents: insights from in silico molecular docking studies, ADME analysis. J Mol Struct 1366. https:\/\/doi.org\/10.1016\/j.molstruc.2026.145941","DOI":"10.1016\/j.molstruc.2026.145941"},{"key":"5836_CR34","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1134\/S0006297920090011","volume":"85","author":"AA Rosenkranz","year":"2020","unstructured":"Rosenkranz AA, Slastnikova TA (2020) Epidermal growth factor receptor: key to selective intracellular delivery. Biochem Mosc 85:967\u2013993. https:\/\/doi.org\/10.1134\/S0006297920090011","journal-title":"Biochem Mosc"},{"key":"5836_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s41061-020-00307-5","volume":"378","author":"N Sahiba","year":"2020","unstructured":"Sahiba N, Agarwal S (2020) Recent advances in the synthesis of perimidines and their applications. Top Curr Chem 378:44. https:\/\/doi.org\/10.1007\/s41061-020-00307-5","journal-title":"Top Curr Chem"},{"key":"5836_CR36","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11696-023-03070-1","volume":"78","author":"S Sathish","year":"2024","unstructured":"Sathish S, Devaraju P, Julius A et al (2024) Identification of selective inhibitors for Janus kinase 1: an integrated drug repurposing strategy for breast cancer. Chem Pap 78:245\u2013262. https:\/\/doi.org\/10.1007\/s11696-023-03070-1","journal-title":"Chem Pap"},{"key":"5836_CR37","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1007\/s12010-024-05109-9","volume":"197","author":"S Sathish","year":"2025","unstructured":"Sathish S, Sohn H, Madhavan T (2025) An in silico approach to uncover selective JAK1 inhibitors for breast cancer from life chemicals database. Appl Biochem Biotechnol 197:2508\u20132543. https:\/\/doi.org\/10.1007\/s12010-024-05109-9","journal-title":"Appl Biochem Biotechnol"},{"key":"5836_CR38","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s12247-026-10617-8","volume":"21","author":"S Sathish","year":"2026","unstructured":"Sathish S, Ponnusamy K, Madhavan T (2026) Computational identification of potential JAK1 inhibitors targeting breast cancer: leveraging the SANC database for drug discovery. J Pharm Innov 21:404. https:\/\/doi.org\/10.1007\/s12247-026-10617-8","journal-title":"J Pharm Innov"},{"key":"5836_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.108037","volume":"154","author":"SR Shetty","year":"2025","unstructured":"Shetty SR, Kar T, Das A (2025) Epidermal growth factor receptor mutations in breast cancer: therapeutic challenges and way forward. Bioorg Chem 154:108037. https:\/\/doi.org\/10.1016\/j.bioorg.2024.108037","journal-title":"Bioorg Chem"},{"key":"5836_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1878-0261.12155","volume":"12","author":"S Sigismund","year":"2018","unstructured":"Sigismund S, Avanzato D, Lanzetti L (2018) Emerging functions of the EGFR in cancer. Mol Oncol 12:3\u201320","journal-title":"Mol Oncol"},{"key":"5836_CR41","doi-asserted-by":"publisher","unstructured":"Singh GK, Bajpai J, Joshi S, et al (2020) Excellent response to erlotinib in breast carcinoma with rare EGFR mutation\u2014a case report. Ecancermedicalscience 14. https:\/\/doi.org\/10.3332\/ECANCER.2020.1092","DOI":"10.3332\/ECANCER.2020.1092"},{"key":"5836_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102976","volume":"69","author":"P Wang","year":"2024","unstructured":"Wang P, Zhou R, Zhou R et al (2024) Epidermal growth factor potentiates EGFR(Y992\/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium. Redox Biol 69:102976. https:\/\/doi.org\/10.1016\/j.redox.2023.102976","journal-title":"Redox Biol"},{"key":"5836_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06422-5","volume":"23","author":"Y Xie","year":"2025","unstructured":"Xie Y, Wang X, Wang W et al (2025) Epithelial-mesenchymal transition orchestrates tumor microenvironment: current perceptions and challenges. J Transl Med 23:386. https:\/\/doi.org\/10.1186\/s12967-025-06422-5","journal-title":"J Transl Med"},{"key":"5836_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117714","volume":"181","author":"J Yuan","year":"2024","unstructured":"Yuan J, Yang L, Zhang H et al (2024) Decoding tumor microenvironment: EMT modulation in breast cancer metastasis and therapeutic resistance, and implications of novel immune checkpoint blockers. Biomed Pharmacother 181:117714. https:\/\/doi.org\/10.1016\/j.biopha.2024.117714","journal-title":"Biomed Pharmacother"},{"key":"5836_CR45","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1021\/acs.jcim.8b00458","volume":"59","author":"Z Zhao","year":"2019","unstructured":"Zhao Z, Xie L, Bourne PE (2019) Structural insights into characterizing binding sites in epidermal growth factor receptor kinase mutants. J Chem Inf Model 59:453\u2013462. https:\/\/doi.org\/10.1021\/acs.jcim.8b00458","journal-title":"J Chem Inf Model"},{"key":"5836_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103131","volume":"91","author":"D-C Zhou","year":"2019","unstructured":"Zhou D-C, Lu Y-T, Mai Y-W et al (2019) Design, synthesis and biological evaluation of novel perimidine o-quinone derivatives as non-intercalative topoisomerase II catalytic inhibitors. Bioorg Chem 91:103131. https:\/\/doi.org\/10.1016\/j.bioorg.2019.103131","journal-title":"Bioorg Chem"},{"key":"5836_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032651","author":"T Zubair","year":"2023","unstructured":"Zubair T, Bandyopadhyay D (2023) Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24032651","journal-title":"Int J Mol Sci"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05836-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05836-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05836-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:00:18Z","timestamp":1789538418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05836-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":47,"alternative-id":["5836"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05836-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"6 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}